Across TCGA pan-cancer cohorts, OGDHL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OGDHL data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher OGDHL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated OGDHL expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where OGDHL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.996	0.679	.003	25	view →
UCEC	DFS	Median	III,IV	0.460	0.889	.044	8	view →
LSCC	DFS	Median	III,IV	1.000	0.399	.049	2	view →
GBM	OS	Tertile	All	0.906	0.773	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OGDHL tumor-vs-normal RNA expression · all OGDHL data types